Cellics Therapeutics

What Cellics Therapeutics does

Cellics Therapeutics is a privately held, early-stage biotechnology company founded in 2014 and headquartered at 11588 Sorrento Valley Rd., Suite #20, San Diego, California. The company describes itself as developing biomimetic nanomedicines intended to address significant unmet medical needs in inflammation and immunology, positioning around a novel therapeutics platform rather than a disclosed named product or pipeline. Its corporate website is a 'Coming Soon' placeholder and no specific drug candidates, modalities, indications, clinical milestones, patents, certifications, or partnerships are disclosed in available materials.

The company has financed operations entirely through equity and non-dilutive capital, accumulating approximately $36.9M across five disclosed rounds between 2016 and 2022, including a CARB-X award in October 2020 indicating activity in antimicrobial-resistance therapeutics in addition to its inflammation/immunology positioning. Headcount is reported in the 11-50 range, consistent with a small R&D-stage team. There is no disclosed revenue, pricing model, or commercial channel because the company has not reached clinical or regulatory milestones that would enable product commercialization; distribution, pricing, and customer-facing infrastructure are therefore not yet applicable.

From a business-model standpoint, Cellics is a development-stage therapeutics company whose economics will depend on future licensing, partnership, or product-sale outcomes following clinical advancement and regulatory approval rather than current-period revenue. No management team, board composition, subsidiary structure, or strategic partnerships are disclosed beyond a founder attribution and a fragmented leadership roster. The overall signal is of a small, founder-led, capital-efficient nanomedicine platform that has secured multi-year funding but lacks public visibility into its current pipeline, clinical status, or forward funding trajectory.

Name

Cellics Therapeutics

Legal name

Cellics Therapeutics

Website

https://cellics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellics Therapeutics is a privately held, early-stage San Diego biotechnology company developing biomimetic nanomedicines to address unmet needs in inflammation and immunology, with no commercial products or disclosed revenue.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Biomimetic nanomedicines
• Inflammation therapeutics
• Immunology drug development
• Novel therapeutics platform
• Biotechnology drug discovery

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels1 record

Core offering

Cellics Therapeutics is developing a novel therapeutics platform using biomimetic nanomedicines to address significant unmet needs in inflammation and immunology. The company operates as a single platform-based offering in the pre-commercial development stage, with its product pipeline marked as "Coming Soon" on the company website. No specific named products, modules, or commercial-stage offerings have been disclosed in available source materials.

Product overview

Cellics Therapeutics offers a novel therapeutics platform focused on addressing unmet needs in inflammation and immunology. The company appears to operate as a single platform-based offering rather than a multi-product portfolio, though no specific named products, modules, or sub-brand offerings are detailed in the available source materials.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomimetic nanomedicines therapeutics platform (in development) A novel therapeutics platform based on biomimetic nanomedicines targeting unmet needs in inflammation and immunology. Currently in pre-commercial development with a "Coming Soon" status on the company website; no named commercial products, modules, or sub-brand offerings are disclosed.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights4 records

Emerging players

• Intellia Therapeutics: Clinical-stage biotech developing in vivo gene editing therapies using lipid nanoparticle delivery for inflammatory and genetic diseases. Comparable as an early-stage, platform-based therapeutics company innovating in delivery technologies.
• Equillium: Clinical-stage biotechnology company developing immunomodulatory therapies for severe autoimmune and inflammatory disorders. Comparable as a focused inflammation/immunology therapeutics company in early-stage development.
• RAPT Therapeutics: Clinical-stage immunology company developing oral small molecules for inflammatory diseases. Comparable as a focused inflammation therapeutics peer in similar development stage.
• Landos Biopharma: Clinical-stage biopharmaceutical company developing novel oral therapeutics for autoimmune diseases. Comparable as an early-stage immunology therapeutics developer.
• Laronde (Eclipse Bioinnovations successor): Developed programmable RNA medicines via the Endless RNA (eRNA) platform and nanoparticle delivery. Comparable as an innovative delivery-platform therapeutics company in the inflammation/immunology adjacent space.
• Capstan Therapeutics: Develops cell-targeted lipid nanoparticle therapeutics, including in vivo CAR-T cell engineering approaches. Comparable as a delivery-platform company leveraging biomimetic and nanoparticle technologies for immunology.

Direct peers

• Selecta Biosciences: Develops immune tolerance technologies, including nanoparticle-based approaches to treat autoimmune and inflammatory diseases. Comparable as a nanoparticle-delivery therapeutics company targeting immunology indications.
• Arcturus Therapeutics: Focused on RNA-based therapeutics and lipid nanoparticle delivery technologies. Arcturus is comparable as a delivery-platform-centric therapeutics developer tackling inflammation and rare diseases with novel nanoparticle modalities.
• Rubius Therapeutics: Develops engineered red blood cell-based therapeutics, including products for immunology and inflammation. Rubius is the closest direct peer to Cellics given its use of cell-membrane-derived biomimetic approaches to address inflammatory and immune diseases.

Others

• CytoSorbents Corporation: Commercial-stage company using biomimetic blood-purification polymer technology to treat inflammatory conditions in critical care. Comparable as a biomimetic-medicine adjacent technology company addressing inflammation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/cellics-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellics Therapeutics